biotech.today

Details

  • Modalities: antibodies, biologics
  • Therapeutic areas: oncology, immunology
  • Key targets:
  • Indications: Undisclosed
  • Funding: Undisclosed

Partners & investors

  • Almirall· Investor
  • AstraZeneca· Investor

Key considerations

  • AI tools in use: Absci Platform, IgDesign
  • IPO 2021 (Nasdaq:ABSI)
  • IgDesign publication 2024
  • Multiple biobuck deals including AstraZeneca and Almirall

Pipeline

  • Phase 11
Get live updates on Absci Corporation’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Sean McClain

Founder & CEO

ai-biologicsabsci
Visit website →LinkedIn →